The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback